Ferric Derisomaltose for Heart Failure and Iron Deficiency

Key Messages

What Is the Issue?

• Iron deficiency is a common comorbidity in patients with heart failure.
• Decision-makers are interested in understanding the clinical efficacy and safety of ferric derisomaltose in the treatment of patients with heart failure and iron deficiency.

What Did We Do?

• We searched key resources, including journal citation databases, and conducted a focused internet search for relevant evidence published since 2020.

What Did We Find?

• Clinical evidence suggests that ferric derisomaltose results in limited improvement in health-related quality of life in the short-term, without any effect on mortality, hospitalization, or exercise capacity compared to usual care.
• There was a reduction in the frequency of cardiovascular death or hospitalization for stroke, myocardial infarction, or heart failure in patients who received ferric derisomaltose compared to patients who received usual care, but the evidence was uncertain due to imprecision and risk of bias. Safety outcomes were similar in both groups of patients.
• An evidence-based guideline suggests that clinicians may consider 1 of 3 IV iron products, including ferric derisomaltose, for the treatment of patients with heart failure with reduced ejection fraction and iron deficiency, despite a lack of sufficient evidence to support a strong recommendation for IV iron therapy.
• We did not identify any evidence on the comparative clinical efficacy and safety of ferric derisomaltose compared to ferric carboxymaltose or other IV iron products in adult patients with heart failure and iron deficiency.

What Does It Mean?

• There was insufficient evidence to strongly support the use of IV ferric derisomaltose for the treatment of patients with heart failure with reduced ejection fraction and iron deficiency.
• It is not known how well ferric derisomaltose works or how safe it is compared with ferric carboxymaltose or other IV iron treatments in adults with heart failure and iron deficiency.
• Additional evidence is necessary to inform decision-making regarding the use of ferric derisomaltose for the treatment of adults with heart failure and iron deficiency.